Dataset Information

Microarray analysis to identify differential molecular signatures in subjects with stable coronary artery disease on standard dosage regimens versus healthy controls

ABSTRACT: In the present study, we used a top-down approach using microarray analysis to evaluate the novel molecular signatures that differentiate between subjects with stable coronary artery disease and normal healthy controls and which remain unresponsive to the standard therapies currently in clinical practice . Micro-array analysis revealed that inspite of concerted treatment efforts 513 genes were differentially expressed in our patient group vs healthy controls.

ORGANISM(S): Homo sapiens

PROVIDER: GSE56885 | GEO | 2015/04/16

SECONDARY ACCESSION(S): PRJNA244863

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Terminalia arjuna (Roxb.) Wight & Arn., a well known Traditional medicine an. popularly known as Arjuna, has a long antiquity of its role as a cardiac stimulant, and has been stipulated in the treatment of hypercholesterolemia, heart failure and atherosclerosis. The present study was carried out to access the effects of Terminalia arjuna as an adjuvant therapy in angiographically proven patients with stable coronary artery disease who were on conventional medications. The goal of the study was to establish whether Terminalia arjuna exerts beneficial effects in targetting disease signatures which remain unresponsive to the standard therapies currently employed in the clinics. The present study scientifically validates the therapeutic effects of this medicinal plant as an adjuvant therapy along with conventional drugs routinely used in the clinics for prevention and treatment of coronary artery disease. To access the effect of T.arjuna, a placebo-controlled, double blind randomized study was carried out in 100 angiographically proven non-diabetic patients with coronary artery disease having disease more than 3 months prior to their enrollment and using any combination of cardiac-related medications including ASA, ACEIs, ARBs, β-blockers and statins (Trial Registration Number : REF/2013/03/004810). Out of total 100 patients, 50 patients were on drug A and 50 patients were on drug B for a total duration of 6 months (Follow-up at 3 and 6 months). Both Drug as well as placebo was given in the form of capsule (500mg) provided by The Himalaya Drug Company, Bangalore. Method of concealment was through coded identical containers. All the participants, investigator, outcome Assessor and data-entry operator were blinded during the whole study. Micro-array was performed in 2 randomly selected patients in each sub-group i.e. Terminalia arjuna or Placebo at 3 and 6 months respectively. RNA extraction and hybridization was carried out using Affymetrix microarrays. Differential expression of genes in T.arjuna-treated and Placebo groups was studied to understand the specificity, efficacy and mechanism of action of T.arjuna.

Dataset Information

Microarray analysis to identify differential molecular signatures in subjects with stable coronary artery disease on standard dosage regimens versus healthy controls

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure